Here, neither MAFbx nor PGC1-α showed marked changes during NSCLC cancer development or in response to metformin treatment, suggesting that conditions in this study were not sufficient to induce rapid atrophy (<6 weeks). The gene discussed is FBXO32; the disease is non-small cell lung carcinoma.